BG108427A - 2,5-диарилпиразини, 2,5-диарилпиридини и 2,5-диарилпиримидини като модулатори на crf1 рецептори - Google Patents

2,5-диарилпиразини, 2,5-диарилпиридини и 2,5-диарилпиримидини като модулатори на crf1 рецептори

Info

Publication number
BG108427A
BG108427A BG108427A BG10842703A BG108427A BG 108427 A BG108427 A BG 108427A BG 108427 A BG108427 A BG 108427A BG 10842703 A BG10842703 A BG 10842703A BG 108427 A BG108427 A BG 108427A
Authority
BG
Bulgaria
Prior art keywords
compounds
disorders
diarylpyridines
diairpyrazines
diarylpyrimidines
Prior art date
Application number
BG108427A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jianhua Huang
Kevin Hodgetts
Dario Doller
Ping Ge
Yasuchika Yamaguchi
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of BG108427A publication Critical patent/BG108427A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BG108427A 2001-06-12 2003-12-08 2,5-диарилпиразини, 2,5-диарилпиридини и 2,5-диарилпиримидини като модулатори на crf1 рецептори BG108427A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29748301P 2001-06-12 2001-06-12

Publications (1)

Publication Number Publication Date
BG108427A true BG108427A (bg) 2005-01-31

Family

ID=23146501

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108427A BG108427A (bg) 2001-06-12 2003-12-08 2,5-диарилпиразини, 2,5-диарилпиридини и 2,5-диарилпиримидини като модулатори на crf1 рецептори

Country Status (16)

Country Link
US (2) US6887875B2 (enExample)
EP (1) EP1399428A1 (enExample)
JP (1) JP2005500286A (enExample)
AP (1) AP2003002924A0 (enExample)
BG (1) BG108427A (enExample)
CA (1) CA2450262A1 (enExample)
EC (1) ECSP034898A (enExample)
HR (1) HRP20031096A2 (enExample)
HU (1) HUP0400179A3 (enExample)
IL (1) IL159058A0 (enExample)
IS (1) IS7060A (enExample)
MX (1) MXPA03011391A (enExample)
PL (1) PL367476A1 (enExample)
RU (1) RU2003136151A (enExample)
TN (1) TNSN03133A1 (enExample)
WO (1) WO2002100838A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4368001A (en) * 2000-03-16 2001-09-24 Neurogen Corporation 5-substituted arylpyrimidines
BR0309551A (pt) 2002-04-26 2005-02-09 Upjohn Co Derivados substituìdos de pirazina
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
AU2003278542A1 (en) * 2002-11-21 2004-06-15 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators
BRPI0416853A (pt) 2003-11-24 2007-02-13 Hoffmann La Roche pirazolila e imidazolila pirimidinas
BRPI0513211A (pt) * 2004-07-14 2008-04-29 Basf Ag composto, agente pesticida, combinação, e, processos para combater fungos nocivos fitopatogênicos, e pestes animais em agricultura
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
BRPI0614262A2 (pt) * 2005-08-02 2011-03-15 Lexicon Pharmaceuticals Inc aril piridinas e métodos para uso das mesmas
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
WO2011051478A1 (en) * 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9351494B2 (en) 2013-05-03 2016-05-31 Inscent, Inc. Honeybee repellents and uses thereof
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN105254576A (zh) * 2014-02-26 2016-01-20 中国科学院长春应用化学研究所 一种谷氨酸二酮哌嗪的制备方法
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
JP2022074173A (ja) * 2019-03-18 2022-05-18 住友化学株式会社 2,5-ジクロロピラジンの製造方法
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN113429354A (zh) * 2021-07-22 2021-09-24 广东嘉博制药有限公司 一种盐酸甲氧明聚合物杂质及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463813A (fr) * 1964-02-26 1966-07-22 Ciba Geigy Nouvelles amino-phénylcétones et procédé pour leur préparation
US3660404A (en) * 1969-02-24 1972-05-02 Du Pont U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls
DE2064380C3 (de) * 1970-12-30 1981-01-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Gemisch
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
EP0339252B1 (en) * 1988-04-25 1996-06-12 Dainippon Ink And Chemicals, Inc. 2,5-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same
JPH02209873A (ja) * 1989-02-08 1990-08-21 Dainippon Ink & Chem Inc 光学活性2,5―ジ置換ピリミジン誘導体
JP2770385B2 (ja) * 1989-03-16 1998-07-02 セイコーエプソン株式会社 ピリミジン誘導体
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体
JPH0948760A (ja) * 1995-08-03 1997-02-18 Dainippon Ink & Chem Inc ピリミジン化合物
JP4044175B2 (ja) * 1996-07-26 2008-02-06 株式会社半導体エネルギー研究所 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
PL341984A1 (en) * 1998-01-28 2001-05-07 Shionogi & Co Novel tricycle compounds
CO5210940A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine

Also Published As

Publication number Publication date
IS7060A (is) 2003-11-28
IL159058A0 (en) 2004-05-12
HUP0400179A2 (hu) 2004-08-30
WO2002100838A1 (en) 2002-12-19
TNSN03133A1 (en) 2005-12-23
JP2005500286A (ja) 2005-01-06
US20050176721A1 (en) 2005-08-11
HRP20031096A2 (en) 2005-08-31
CA2450262A1 (en) 2002-12-19
EP1399428A1 (en) 2004-03-24
AP2003002924A0 (en) 2003-12-31
US6887875B2 (en) 2005-05-03
HUP0400179A3 (en) 2004-10-28
US20030119844A1 (en) 2003-06-26
MXPA03011391A (es) 2004-07-01
RU2003136151A (ru) 2005-05-20
PL367476A1 (en) 2005-02-21
ECSP034898A (es) 2004-01-28

Similar Documents

Publication Publication Date Title
TNSN03133A1 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
TNSN03119A1 (en) 5-substituted-2-arylpyridines as crf1 modulators
EA200600372A1 (ru) Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1)
WO2005028480A3 (en) 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
NO20021357L (no) Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner
WO2005115399A3 (en) Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
BG106506A (en) ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES
YU34898A (sh) Antagonisti ccr-3 receptora
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
GEP20074197B (en) 5ht2c receptor modulators
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
ATE461178T1 (de) Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden
SE0101038D0 (sv) Novel compounds
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
WO2001068614A3 (en) 5-substituted arylpyrimidines
ATE402958T1 (de) Antagonisten des ige-rezeptors
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
DE602006005254D1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden